Each film-coated tablet contains Atenolol 50 mg.
Atenolol (Tenorvas) is a β1 selective adrenergic receptor antagonist. It competitively blocks β1 (cardiac) receptors and thus acts as an antihypertensive medication. It has no effect on β2-receptors. Atenolol (Tenorvas) significantly reduces both maximal and submaximal exercise heart rates.
Pharmacology: Pharmacokinetics: Atenolol (Tenorvas) is incompletely absorbed from the gastrointestinal tract; following oral administration about 50% is absorbed. Peak plasma concentrations are reached in 2 to 4 hours. Atenolol (Tenorvas) has low lipid solubility. It crosses the placenta and is distributed into breast milk where concentrations higher than those in maternal plasma have been achieved. Only small amounts are reported to cross the blood-brain barrier, and plasma-protein binding is minimal. The plasma half-life is about 6 to 7 hours. Atenolol (Tenorvas) undergoes little or no hepatic metabolism and is excreted mainly in the urine.
Atenolol (Tenorvas) is indicated in hypertension, angina pectoris, myocardial infarction and cardiac arrhythmias. It may also be used in the prophylactic treatment of migraine.
Hypertension: Initially 25-50 mg daily, the dosage gradually may be increased up to 50-100 mg.
Angina pectoris: 100 mg daily in 1-2 divided doses.
Arrhythmias: 50-100 mg daily.
Or as directed by the physician.
Atenolol (Tenorvas) is contraindicated in sinus bradycardia, heart failure, second and third degree heart block. Atenolol (Tenorvas) should not be used in patients with any of the following: Known hypersensitivity to the substance; cardiogenic shock, hypotension, metabolic acidosis, severe peripheral circulatory disturbances, sick sinus syndrome, untreated phaeochromocytoma and uncontrolled heart failure.
Atenolol (Tenorvas) should be administered cautiously in pregnant and lactating mother. Oral dose should be reduced in case of renal failure.
Atenolol (Tenorvas) should be administered cautiously in pregnant and lactating mother.
Reports of sclerosing peritonitis and retroperitoneal fibrosis in patients taking atenolol. Beta blockers are used in the management of cardiac arrhythmias. However, Atenolol 2.5 mg by intravenous injection induced atrial fibrillation in 6 of 12 predisposed patients. A report of reversible cholestatic hepatitis in a patient receiving atenolol and hepatic dysfunction is another. Visual symptoms without headache is associated with atenolol for migraine prophylaxis in a patient who had experienced a similar reaction with nadolol. Precipitous falls in blood pressure in patients with malignant hypertension may cause ischaemic damage to vital organs. Initiating treatment with 1 or 2 oral drugs is considered appropriate but not without risk. Two cases of hypotension following a single oral dose of atenolol 100 mg (27 year old woman) and following 2 oral doses of atenolol 50 mg (51 year old woman) have been reported. The woman had presented with severe hypertension, hyponatraemia, hypokalaemia, and high renin activity. There was a transient elevation of serum creatinine in both patients indicating kidney ischaemia. Renal artery thrombosis believed to be due to the hypotensive effect of atenolol was reported in a 70 year old man with a history of circulatory and cardiac disorders. He had received atenolol 100 mg for treatment of moderate hypertension.
Store at temperatures not exceeding 30°C. Protect from light.
C07AB03 - atenolol ; Belongs to the class of selective beta-blocking agents. Used in the treatment of cardiovascular diseases.